VANESSA TAY TRAVECTA THRAPUETICS

Company Type: Biotechnology Company / Developer of Therapeutics

Company Introduction:

Travecta Therapeutics is a Singapore-headquartered biotechnology company focused on the discovery and development of innovative therapies for diseases with high unmet medical needs. The company specializes in leveraging its proprietary "Blood-Brain Barrier (BBB) technology" to enable the targeted delivery of therapeutic molecules across the brain-blood barrier. This technology addresses a significant challenge in treating neurological disorders and brain cancers. As a biotechnology firm, Travecta Therapeutics is primarily involved in research, development, and the eventual manufacture of novel pharmaceutical products, positioning it as a developer and producer of therapeutics rather than a trading company that buys and sells existing goods. Vanessa Tay is a co-founder and the CEO of Travecta Therapeutics.

Company: Travecta Therapeutics

Location: Singapore

Products (currently in development or proprietary technology):

Proprietary Drug Delivery Platform: This is an innovative technology based on a unique transporter system. It is designed to enable various therapeutic molecules (including small molecules, biologics, and gene therapies) to effectively cross biological barriers, such as the blood-brain barrier, for targeted delivery to the central nervous system.

TRV001: This is their lead drug candidate, which is currently under development for the treatment of various neurological disorders.